rhG-CSF对140例恶性肿瘤化放疗所致白细胞减少的临床疗效观察

Curative Effect of rhG-CSF on Leukopenia Induced by Chemoradiotherapy in 140 Cases of Malignant Tumors

为了观察rhG CSF对恶性肿瘤放化疗所致白细胞减少的疗效 ,对 14 0例恶性肿瘤放化疗所致粒细胞减少的患者用此国产rhG CSF(粒生素 )进行治疗。白细胞 <3.0× 10 9/L或中性粒细胞绝对计数 (ANC) <2 .0× 10 9/L时开始用粒生素 75 μg,皮下注射 ,每日 1次 ,待白细胞 >4 .0× 10 9/L或中性粒细胞绝对计数 >2 .5× 10 9/L时停药。结果表明 :粒生素能使放化疗所致粒细胞减少回升至正常范围 ,平均时间为 4 8天 ,有效率 96 .4 %。结论 :粒生素可以明显减轻放化疗过程中外周血白细胞下降程度 ,缩短白细胞恢复时间 ,且毒副反应轻、安全可靠 ,有利于放化疗的顺利进行。

This study was to evaluate the effect of a Chinese genetic engineering product of rhG-CSF (Lishengsu) on leukopenia induced by chemoradiotherapy in patients with malignant solid tumors. One hundred and forty cases of leukopenia following chemoradiotherapy for malignant tumors were treated with Lishengsu. When the total leukocyte counts (WBC) less than 3.0×10 9/L or the absolute neutrophil count (ANC) less than 2.0×10 9/L, Lishengsu was given 75 μg/day subantaneously and the administration was stopped when the WBC counts rose up to 4.0×10 9/L or higher, or the ANC counts reached 2.5×10 9/L or more. The results showed that peripheral leukocyte counts in all patients following the treatment with Lishengsu were recovered and the average time of its administration was 4.8 days. The rate of its efficaciousness was 96.4%. It is concluded that Lishengsu could elevate nadirs of leukopenia and significantly shortened time period of leukopenia below 4.0×10 9/L with acceptable mild side effects, decrease complications of infection so that the chinese product of rhG-CSF facilitates chemoradiotherapy significantly.